OneMedNet Corporation has partnered with Onco-Innovations and its subsidiary Inka Health to accelerate oncology drug development using OneMedNet’s AI-powered real-world data platform, iRWD™, supported by Palantir Foundry. This collaboration aims to enhance development timelines, reduce risks, and improve evidence generation for Onco-Innovations’ PNKP Inhibitor Technology targeting PTEN/SHP1-deficient cancers. The partnership will focus on identifying patient responders, expanding indications, and supporting clinical and regulatory decisions. This initiative leverages advanced AI and multi-modal data to find rare patient populations and improve cancer treatment innovation.
YieldMax Ultra Option Income Strategy ETF (ULTY) promises a high annualized yield near 62% through weekly distributions by selling options on volatile tech stocks. However, its total return over the past year was -4.8%, far below the S&P 500's 22% ga...
Palantir reported an 85% increase in revenue while keeping operating expenses to a 32% rise, resulting in 60% adjusted operating margins and 57% free cash flow margins. The company's earnings and free cash flow are growing faster than sales due to st...
TappAlpha introduced the TappAlpha Cboe Magnificent 10 Growth & Daily Income ETF (TMGN), which offers exposure to the Cboe Magnificent 10 Index featuring leading tech companies like Nvidia, Microsoft, and Apple. This ETF applies TappAlpha's options-b...
Tech investor Chamath Palihapitiya warned that the rising costs of artificial intelligence (AI) usage might negatively impact some companies' earnings. He highlighted that many CEOs and CFOs are unaware of the extent of AI-related spending, which cou...
The REX AI Equity Premium Income ETF (AIPI) changed its distribution schedule from monthly to weekly payments while maintaining a similar annual yield near 35%. The fund generates income by selling call options on AI-focused stocks like Palantir and ...
